How should deletion 13q in chronic lymphocytic leukemia be managed?

Management of Deletion 13q in Chronic Lymphocytic Leukemia

Deletion 13q as a sole abnormality in CLL is associated with favorable prognosis and does not require immediate treatment, but you must assess both the clone size (percentage of cells with deletion) and deletion size (whether RB1 is involved) to refine risk stratification and predict time to treatment. 1, 2

Initial Prognostic Assessment

When del(13q) is detected as an isolated abnormality, perform the following stratification:

Clone Size Assessment

• Measure the percentage of nuclei with del(13q) using FISH analysis
• Patients with ≥60-80% of cells carrying del(13q) have significantly shorter time to first treatment and worse overall survival 3, 4, 5
• Those with <70% deleted nuclei experience particularly long treatment-free intervals 5

Deletion Size Characterization

• Use dual FISH probes: LSI-D13S319 (detecting DLEU2/MIR15A/MIR16-1) and LSI-RB1 5
• Type I deletions (small, excluding RB1): Better prognosis
• Type II deletions (large, including RB1): Associated with shortened survival and increased genomic complexity, occurring in ~20% of all CLL patients 6

Risk Stratification Algorithm

Best prognosis group:

• <70% deleted nuclei AND Type I deletion (RB1-negative)
• These patients have the longest treatment-free survival 5

Intermediate prognosis group:

• <70% deleted nuclei BUT Type II deletion (RB1-positive) 5

Higher risk group:

• ≥70% deleted nuclei, regardless of RB1 status 5
• Type II deletions with ≥60-80% clone size 3, 4

Critical Caveats and Testing Considerations

Hidden Microdeletions

Standard FISH may miss microdeletions of the miR-15a/16-1 locus - approximately 34% of CLL cases show unreported loss of this critical region that standard FISH doesn't detect 7. This is particularly important because:

• ~39% of trisomy 12 cases carry undetected miR-15a/16-1 microdeletions 7
• ~40% of cases with 17p- or 11q- also harbor these microdeletions 7

Integration with Other Prognostic Markers

Refine risk assessment by combining del(13q) characteristics with:

• Binet stage: In Binet A or B patients, high clone size (≥80%) predicts significantly shorter time to treatment (median 18 months vs undefined) 3
• IGHV mutation status: In IGHV-mutated patients, high del(13q) clone size still confers worse prognosis (median TTT 18 months vs undefined) 3
• CLL-IPI score: Incorporate del(13q) findings into comprehensive prognostic assessment 1

Monitoring Strategy

Repeat FISH testing for del(17p) and TP53 mutation before each line of therapy 1, as clonal evolution can occur during disease course. The favorable prognosis of isolated del(13q) can change if additional abnormalities emerge.

Watch for Additional Abnormalities

• Gain of 16p13.3 has been identified as a potential new adverse prognostic marker associated with shorter time to first treatment and advanced stage 8
• Increased genomic complexity often accompanies Type II deletions 6

Treatment Implications

For isolated del(13q) with favorable features (low clone size, Type I deletion):

• Observation is appropriate; median survival can exceed 133 months 2
• These patients fall into the low-risk CLL-IPI category that should not be treated 1

For isolated del(13q) with unfavorable features (high clone size and/or Type II deletion):

• Consider these patients as intermediate-risk
• When treatment is indicated, both chemoimmunotherapy and targeted agents (BCR inhibitors, venetoclax) are effective, as del(13q) does not confer chemotherapy resistance like del(17p) 1

The heterogeneity within isolated del(13q) CLL is substantial 9, making detailed characterization essential for accurate prognostication and avoiding premature or delayed treatment decisions.